圣湘生物：控股子公司获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Shengxiang Biotechnology Co., Ltd. announced that its subsidiary, Zhongshan Shengxiang Haiji Biotechnology Co., Ltd., received approval from the National Medical Products Administration for a supplementary application to use its human growth hormone injection for the treatment of idiopathic short stature (ISS) [1] Group 2 - The product's supplementary application for clinical trials has been officially approved by the National Medical Products Administration [1]